Enterprise-Record (Chico)

US opens COVID boosters to all adults, urges them for 50+

- By Lauran Neergaard, Matthew Perrone and Mike Stobbe

The U.S. on Friday opened COVID-19 booster shots to all adults and took the extra step of urging people 50 and older to seek one, aiming to ward off a winter surge as coronaviru­s cases rise even before millions of Americans travel for the holidays.

Until now, Americans faced a confusing list of who was eligible for a booster that varied by age, their health and which kind of vaccine they got first. The Food and Drug Administra­tion authorized changes to Pfizer and Moderna boosters to make it easier.

Under the new rules, anyone 18 or older can choose either a Pfizer or Moderna booster six months after their last dose. For anyone who got the singledose Johnson & Johnson vaccine, the wait already was just two months. And people can mix-and-match boosters from any company.

Keeping it simple

“We heard loud and clear that people needed something simpler — and this, I think, is simple,” FDA vaccine chief Dr. Peter Marks told The Associated Press.

The Centers for Disease Control and Prevention had to agree before the new policy became official late Friday. CDC Director Dr. Rochelle Walensky endorsed a recommenda­tion from her agency’s scientific advisers that — in addition to offering all adults a booster — had stressed that people 50 and older should be urged to get one.

“It’s a stronger recommenda­tion,” said CDC adviser Dr. Matthew Daley of

Kaiser Permanente Colorado. “I want to make sure we provide as much protection as we can.”

The CDC also put out a plea for those who had previously qualified but hadn’t yet signed up for a booster to quit putting it off — saying older Americans and people with risks such as obesity, diabetes or other health problems should try to get one before the holidays.

The expansion makes tens of millions more Americans eligible for an extra dose of protection.

The No. 1 priority for the U.S., and the world, still is to get more unvaccinat­ed people their first doses. All three COVID-19 vaccines used in the U.S. continue to offer strong protection against severe illness, including hospitaliz­ation and death, without a booster.

But protection against infection can wane with time, and the U.S. and many countries in Europe

also are grappling with how widely to recommend boosters as they fight a winter wave of new cases. In the U.S., COVID-19 diagnoses have climbed steadily over the last three weeks, especially in states where colder weather already has driven people indoors.

Not waiting

And about a dozen states didn’t wait for federal officials to act before opening boosters to all adults.

“The direction is not a good one. People are going inside more and, ‘oops,’ next week happens to be the largest travel week of the year, so it probably makes sense to do whatever we can here to try to turn the tide,” Marks told the AP.

Vaccinatio­ns began in the U.S. last December, about a year after the coronaviru­s first emerged. More than 195 million Americans are now fully vaccinated, defined as having received two doses of the Pfizer or

Moderna vaccines or the single-dose J&J. More than 32 million already have received a booster, a large proportion — 17 million — people 65 or older. Experts say that’s reassuring as seniors are at particular­ly high risk from COVID-19 and were among the first in line for initial vaccinatio­ns

Teen boosters aren’t yet under discussion, and kidsized doses of Pfizer’s vaccine are just now rolling out to children ages 5 to 11.

The Biden administra­tion had originally planned on boosters for all adults but until now, U.S. health authoritie­s — backed by their scientific advisers — had questioned the need for such a widespread campaign. Instead, they first endorsed Pfizer or Moderna boosters only for vulnerable groups such as older Americans or those at high risk of COVID-19 because of health problems, their jobs or their living conditions.

 ?? MATT ROURKE — THE ASSOCIATED PRESS FILE ?? A syringe is prepared with the Pfizer COVID-19vaccine at a clinic at the Reading Area Community College in Reading, Pa.
MATT ROURKE — THE ASSOCIATED PRESS FILE A syringe is prepared with the Pfizer COVID-19vaccine at a clinic at the Reading Area Community College in Reading, Pa.

Newspapers in English

Newspapers from United States